Bummer! You're not a
Stitcher Premium subscriber yet.
Learn More
Start Free Trial
$4.99/Month after free trial

Show Info

Episode Info

Episode Info: Guest: William C. Cromwell, MD, FAHA, FNLA Ample data have demonstrated when LDL cholesterol and alternative measures – LDL-P or apo B – disagree, the risk for CVD events tracks with LDL-P or apo B. Additionally, it’s been demonstrated that when patients at high risk for CVD events were managed with the alternative measure LDL-P to 1,000 nmol/L versus less than 100 mg/dL, these patients experienced a 22 percent to 25 percent reduction in CVD events at 12, 24 and 36 months. Importantly, only a small number of individuals needed to be treated to an LDL-P of less than 1000 nmol/L to prevent one CVD event at 36 months. Dr. William Cromwell, medical director for cardiovascular disease at LabCorp, will address these issues. Click here to learn more in this special series.Read more »

Discover more stories like this.

Like Stitcher On Facebook


Episode Options

Listen Whenever

Similar Episodes

Related Episodes